Large Randomized Trial Comparing Expanded versus Conventional Hemodialysis in Adults with Kidney Disease

What this Trial Is About

This research aims to evaluate the health effects of expanded hemodialysis compared to conventional hemodialysis in patients receiving regular hemodialysis treatment. The main goal is to determine whether expanded hemodialysis lowers the risk of death from any cause. The trial is a large, randomized controlled study involving 4,800 participants followed for an average of 2.9 years, with results expected in 2030. Participants will receive their usual hemodialysis treatments using either a super high-flux dialyzer Nipro Elisio HX that removes larger molecules more effectively or a conventional high-flux dialyzer used in standard care. The study is open label and randomly assigns participants to either the expanded or conventional hemodialysis group. Treatments continue as usual without additional visits or tests. During the study, data will be collected through healthcare records and medical record reviews at some locations. Researchers will monitor outcomes such as all-cause mortality, cardiovascular and infection-related hospitalizations, and kidney transplant events over the study period. The total study duration includes participant accrual over two years with a mean follow-up near three years.

DIALysis With EXpanded Solute Removal